Figure S3. Circadian period–lengthening compounds induced alterations in U2OS phosphoproteome.
(A) Volcano plots showing P-values (−log10) versus ratio of group mean of phosphosites abundance (log2) in control (DMSO) and longdaysin-, purvalanol A–, roscovitine-, and SP600125-treated cells. Red, up-regulated; green, down-regulated (adjusted P-value < 0.05); and blue, not significantly altered phosphosites. (B) Venn diagram representing overlaps among the differentially abundant phosphoproteins (pAdj < 0.05) identified in longdaysin-, purvalanol A–, roscovitine-, and SP600125-treated cells. (C) Analysis of mean abundance of 123 phosphosites that are altered by circadian period–lengthening compounds. Mean, one-way ANOVA, Dunnett’s test. ** indicates P < 0.001, * indicates P < 0.05. (D) Relative abundance (against DMSO control) of the commonly altered phosphoproteins in longdaysin-, purvalanol A–, roscovitine-, and SP600125-treated cells (mean, n = 3). NS indicates pAdj > 0.05. Mean fold-change is provided for the proteins with multiple altered phosphosites.